Bioavailability

Cannabidiol (CBD) is one of the most prevalent cannabinoids found in hemp and cannabis.

The National Center for Biotechnology Information defines cannabidiol (CBD) as: “A phytocannabinoid derived from Cannabis species, which is devoid of psychoactive activity, with analgesic, anti-inflammatory, antineoplastic and chemopreventive activities”. [1]

CBD works in the human body by binding to and activating CB1 and CB2 receptors, which are part of your body’s endocannabinoid system. Learn more about CBD at ProjectCBD.org

The endocannabinoid system is an endogenous system of physiology involved in sustaining health and wellness. This system is active in everyone, regardless of external cannabinoid consumption. The human body is always producing cannabinoids, which help to regulate a variety of physiological and cognitive processes, including pain reduction, mood, fertility, appetite, and memory. [1] [2]

Cannabidiol has been shown to have analgesic, anti-inflammatory, and anxiety reducing properties. [1] In addition, research has shown that CBD can reduce the psychotic-like symptoms brought on by high doses of Δ(9)-tetrahydrocannabinol (Δ(9)-THC) [2] [3] [4]. According to the National Institute on Drug Abuse, CBD has also been shown to have anti-tumor and neuroprotective properties. [5] In an article published in July of 2018, Medical News Today writes that CBD has received positive attention for its ability to help people deal with pain, epilepsy, anxiety, and a myriad of other ailments. [6]

The simple answer is no. When hemp is in its “plant form”, the quality of the CBD is impacted by variables such as the genetics of the plant, growing conditions, curing techniques, and storage. When the CBD is extracted from the plant, factors such as the general method of extraction, equipment, personnel experience, and refining processes play a significant role in the quality of the CBD.

For FireOrganix, we use extracts as an ingredient in our finished products. We know from experience that years dedicated to R&D in the laboratory, as well as the decades spent furthering our knowledge of nanotechnology, are two (of many) critically important factors to achieve consistent CBD formulations. Not only do we depend on our own experience, but rely on attention to detail within our supply chain, in order to consistently deliver high-performing products with superior bioavailability

Cannabidiol (CBD) and tetrahydrocannabinol (THC) are the two most abundant compounds in the cannabis plant. The most significant difference between CBD and THC is their effects. CBD is non-psychoactive, meaning that it does not produce euphoria or intoxication [1]. THC is the main psychoactive cannabinoid in marijuana and is responsible for the euphoric and intoxicating effects of the cannabis flower. Although CBD and THC can coexist in some strains of cannabis, THC is nearly non-existent in industrial hemp.

In recent years, research has suggested that CBD has numerous benefits in the human body. CBD has been shown to have anti-inflammatory and anxiety-reducing properties. In addition, CBD has had notable success as an anti-epileptic and analgesic medication. Studies have also shown CBD to reduce the psychoactive effects of THC. [1]

Marijuana and industrial hemp are varieties of the Cannabis sativa plant. While very closely related genetically, hemp and marijuana are extremely different in terms of their uses. Hemp is one of the oldest domesticated plants and is known to have been used by humans for over 9,000 years. Today, hemp is grown industrially around the world for a myriad of practical purposes, none of which involve the psychoactive properties of the plant. Industrial hemp is required to contain 0 – < .3% THC. Cannabis, on the other hand, is typically cultivated for its psychoactive properties. Cannabis breeders selectively cross cannabis plants to produce cultivars with specific traits. Some of these traits may include high THC content, high terpene content, and preferred aesthetic traits of the cannabis flower.

Full spectrum is known as “whole-plant” CBD. This means the naturally occuring cannabinoids within the plant, will also exist in the finished product. Full spectrum products typically contain high concentrations of CBD, as well as all other cannabinoids, terpenes, and trace amounts of THC.  The most common minor cannabinoids in a full spectrum product are CBG, CBC, CBN, and THC (<.3%).

Broad spectrum and full spectrum products have a similar cannabinoid profile. However, broad spectrum products do not contain THC. The THC is removed during the extraction process